|Other names||DS-8201a, fam-trastuzumab deruxtecan-nxki|
|Drug class||Antibody-drug conjugate|
|Main uses||Breast cancer, gastric or gastroesophageal adenocarcinoma|
|Side effects||Nausea, tiredness, hair loss, constipation, low red blood cells, low white blood cells, low platelets, headache|
|US NLM||Trastuzumab deruxtecan|
|Chemical and physical data|
Trastuzumab deruxtecan, sold under the brand name Enhertu, is a medication used to treat breast cancer and gastric or gastroesophageal adenocarcinoma. Specifically it is used for HER2 positive disease. It is given by gradual injection into a vein.
Common side effects include nausea, tiredness, hair loss, constipation, low red blood cells, low white blood cells, low platelets, and headache. Other side effects may include low potassium, arrhythmias, interstitial lung disease, and liver problems. Use in pregnancy may harm the baby. It is the monoclonal antibody trastuzumab linked to the topoisomerase I inhibitor deruxtecan. Trastuzumab binds to epidermal growth factor receptor 2 (HER2/neu) while deruxtecan blocks a cell's ability to make DNA.
Trastuzumab deruxtecan was approved for medical use in the United States in 2019, Japan in 2020, Europe and Australia in 2021. In the United Kingdom it costs the NHS about £1,450 as of 2021 for 100 mg. This amount in the United States is about 2,500 USD.
Trastuzumab deruxtecan-nxki is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
The most common side effects are nausea, fatigue, vomiting, alopecia (hair loss), constipation, decreased appetite, anemia (hemoglobin in blood is below the reference range), decreased neutrophil count (white blood cells that help lead your body's immune system response to fight infection), diarrhea, leukopenia (other white blood cells that help the immune system), cough and decreased platelet count (component of blood whose function is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot).
The prescribing information for fam-trastuzumab deruxtecan-nxki includes a boxed warning to advise health care professionals and patients about the risk of interstitial lung disease (a group of lung conditions that causes scarring of lung tissues) and embryo-fetal toxicity. Interstitial lung disease and pneumonitis, including cases resulting in death, have been reported with fam-trastuzumab deruxtecan-nxki.
The U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki in December 2019. The application for fam-trastuzumab deruxtecan-nxki was granted accelerated approval, fast track designation, and breakthrough therapy designation.
The FDA approved fam-trastuzumab deruxtecan-nxki based on the results of one clinical trial enrolling 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies in the metastatic setting. These patients were heavily pretreated in the metastatic setting, receiving between two and 17 therapies prior to receiving fam-trastuzumab deruxtecan-nxki. Patients in the clinical trial received fam-trastuzumab deruxtecan-nxki every three weeks and tumor imaging was obtained every six weeks. The overall response rate was 60.3%, which reflects the percentage of patients who had a certain amount of tumor shrinkage with a median duration of response of 14.8 months.
On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Enhertu, intended for the treatment of metastatic HER2-positive breast cancer. Enhertu was reviewed under EMA's accelerated assessment program. The applicant for this medicinal product is Daiichi Sankyo Europe GmbH. Trastuzumab deruxtecan was approved for medical use in the European Union in January 2021.
In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01, NCT03329690) in participants with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens, including trastuzumab, a fluoropyrimidine- and a platinum-containing chemotherapy. A total of 188 participants were randomized (2:1) to receive fam-trastuzumab deruxtecan-nxki 6.4 mg/kg intravenously every three weeks or physician’s choice of either irinotecan or paclitaxel monotherapy.
- "Fam-Trastuzumab Deruxtecan-nxki Monograph for Professionals". Drugs.com. Retrieved 10 December 2021.
- "FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas". U.S. Food and Drug Administration (FDA). 15 January 2021. Retrieved 15 January 2021. This article incorporates text from this source, which is in the public domain.
- "Enhertu EPAR". European Medicines Agency (EMA). 9 December 2020. Retrieved 31 March 2021.
- "Enhertu". Therapeutic Goods Administration (TGA). 18 October 2021. Retrieved 22 October 2021.
- "Enhertu- fam-trastuzumab deruxtecan-nxki injection, powder, lyophilized, for solution". DailyMed. Retrieved 15 January 2021.
- "Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer" (Press release). AstraZeneca. 20 January 2021. Retrieved 21 January 2021.
- "Enhertu Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer" (Press release). Daiichi Sankyo. 25 March 2020. Retrieved 21 January 2021 – via Business Wire.
- "Trastuzumab deruxtecan". SPS - Specialist Pharmacy Service. 23 December 2018. Retrieved 10 December 2021.
- "Enhertu Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 10 December 2021.
- "FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies". U.S.Food and Drug Administration (FDA) (Press release). 20 December 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019. This article incorporates text from this source, which is in the public domain.
- "Drug Trials Snapshot: Enhertu". U.S. Food and Drug Administration (FDA). 20 December 2019. Retrieved 24 January 2020. This article incorporates text from this source, which is in the public domain.
- "Enhertu: Pending EC decision". European Medicines Agency (EMA). 10 December 2020. Retrieved 11 December 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Trastuzumab deruxtecan recommended for approval in the EU by CHMP for HER2-positive metastatic breast cancer" (Press release). AstraZeneca. 14 December 2020. Retrieved 21 January 2021.
- "Enhertu approved in the US for the treatment of patients with previously treated HER2-positive advanced gastric cancer" (Press release). AstraZeneca. 18 January 2021. Retrieved 22 January 2021.
- "Trastuzumab_deruxtecan". Drug Information Portal. U.S. National Library of Medicine.
- Deruxtecan shows structure
- Iwata TN, Sugihara K, Wada T, et al. (October 2019). "[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model". PLOS ONE. 14 (10): e0222280. doi:10.1371/journal.pone.0222280. PMC 6772042. PMID 31574081.
- Modi S, Saura C, Yamashita T, et al. (February 2020). "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer". N. Engl. J. Med. 382 (7): 610–621. doi:10.1056/NEJMoa1914510. PMC 7458671. PMID 31825192.